Details for New Drug Application (NDA): 022255
✉ Email this page to a colleague
The generic ingredient in VIMPAT is lacosamide. There are twenty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
Summary for 022255
Tradename: | VIMPAT |
Applicant: | Ucb Inc |
Ingredient: | lacosamide |
Patents: | 0 |
Pharmacology for NDA: 022255
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 022255
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
VIMPAT | lacosamide | SOLUTION;ORAL | 022255 | NDA | UCB, Inc. | 0131-5410 | 0131-5410-72 | 200 mL in 1 BOTTLE, GLASS (0131-5410-72) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 10MG/ML | ||||
Approval Date: | Apr 20, 2010 | TE: | AA | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Oct 14, 2024 | ||||||||
Regulatory Exclusivity Use: | NEW PATIENT POPULATION | ||||||||
Regulatory Exclusivity Expiration: | Apr 28, 2026 | ||||||||
Regulatory Exclusivity Use: | USE OF ALTERNATE INITIAL DOSING REGIMEN FOR INITIATION OF LACOSAMIDE TREATMENT IN PARTIAL ONSET SEIZURE PATIENTS ≥1 MONTH TO |
Expired US Patents for NDA 022255
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ucb Inc | VIMPAT | lacosamide | SOLUTION;ORAL | 022255-001 | Apr 20, 2010 | 5,654,301 | ⤷ Subscribe |
Ucb Inc | VIMPAT | lacosamide | SOLUTION;ORAL | 022255-001 | Apr 20, 2010 | RE38551 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription